CCS
PDLI

Crosspoint Capital Strategies’s PDL BioPharma, Inc. PDLI Stock Holding History

Crosspoint Capital Strategies’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,877
Closed -$30K – 1036
2015
Q4 		$30K Buy
+3,877
New +$16.2K 0.01% 523

Other funds holding PDLI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Crosspoint Capital Strategies's PDLI Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 3,877 shares — an estimated $30K sold.

Crosspoint Capital Strategies first reported a position in PDLI in Q4 2015 and held it in 1 quarter. The position peaked at $30K in Q4 2015. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 3,877 PDL BioPharma, Inc. shares in Q1 2016, an estimated $30K.
  • Crosspoint Capital Strategies first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's PDL BioPharma, Inc. position peaked at $30K in Q4 2015.
  • 195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.